Home/Pipeline/NRO-VTN

NRO-VTN

Dry Age-Related Macular Degeneration (AMD)

PreclinicalActive

Key Facts

Indication

Dry Age-Related Macular Degeneration (AMD)

Phase

Preclinical

Status

Active

Company

Neuroptika

About Neuroptika

Neuroptika is a private, preclinical biotech developing innovative treatments for retinal diseases, primarily glaucoma and age-related macular degeneration (AMD). The company's pipeline includes two lead programs: NRO-CMK, a neuroprotective gene therapy for glaucoma targeting retinal ganglion cells, and NRO-VTN, an antibody-based therapy aimed at inhibiting drusen formation in dry AMD. Founded in 2019 and led by a co-CEO team with expertise in science/IP and corporate finance, the company is positioned to address the growing global patient population with significant unmet medical needs. Neuroptika is currently in the preclinical research and development phase.

View full company profile

Therapeutic Areas

Ophthalmology Retinal Diseases

Other Dry Age-Related Macular Degeneration (AMD) Drugs

Drug	Company	Phase	Status
AI Platform Candidates	Biophytis	Discovery	Planned expansion of AI platform to discover next-gen candidates.
LUC-101	Lucina Biotherapeutics	IND-Enabling	Active